# Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

> **NCT06371417** · PHASE1 · RECRUITING · sponsor: **Chugai Pharmaceutical** · enrollment: 144 (estimated)

## Conditions studied

- Antiphospholipid Syndrome (APS)
- Bullous Pemphigoid (BP)
- Behçet's Syndrome (BS)
- Dermatomyositis (DM)
- Immune-mediated Necrotizing Myopathy (IMNM)
- Immune Thrombocytopenia (ITP)

## Interventions

- **DRUG:** RAY121

## Key facts

- **NCT ID:** NCT06371417
- **Lead sponsor:** Chugai Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-19
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06371417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06371417, "Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT06371417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*